

Company name Kamada Ltd. * Website www.kamada.com * CEO name Amir London* *
Select a CATEGORY: Biotech/Pharma Select one SESSION per abstract from the list below * “The Next Pandemic: Are We Ready? Innovation in Infectious Diseases.” •
Kamada Ltd. (NASDAQ: KMDA) is a global biopharmaceutical company with a portfolio of six FDA-approved marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field • Kamada is a global leader in specialty plasma therapies, with an FDA-approved commercial portfolio of hyper-immune globulins (HIG) containing high titers of pathogen- specific IgGs. These products provide rapid passive immunity and are considered cornerstone treatment for some infectious diseases. HIG production, as a platform, is mature, scalable, adaptable, and demonstrably safe. When vaccines are too slow or unavailable, HIGs provide passive immunity, making them an essential countermeasures against high-risk pathogens, emerging infectious diseases and potentially also biological warfare threats. • Pathogen-specific antibodies are enriched at the plasma donor level. To ensure supply of the specialty plasma, Kamada opened several plasma collection centers in the USA. • Kamada's IgG manufacturing technology is an FDA-approved platform which allows rapid development of novel Hyperimmune globulins for emerging diseases. As an example: Kamada's Anti-COVID IgG manufactured using convalescent plasma was the first immunoglobulin therapy globally which entered clinical trials during the COVID pandemic. That experimental preparation was used by the Israeli MOH to treat hundreds of hospitalized patients, including patients with immune deficiencies. • Kamada is growing at a double-digit rate, 2026 annual financial guidance is for \$200M-\$205M in sales and \$50M-\$53M of EBITDA. Main growth drivers include increased usage of Kamada's therapies through better market awareness and geographical expansion, as well as sales of plasma collected at the Company US-based plasma collection centers, and execution of in-licensing/M&A opportunities. • Kamada is growing at a double-digit rate, 2026 annual financial guidance is for \$200M- \$205M in sales and \$50M-\$53M of EBITDA. Main growth drivers include increased usage of Kamada's therapies through better market awareness and geographical expansion, as well as sales of plasma collected at the Company US-based plasma collection centers, and execution of in-licensing/M&A opportunities. • In addition, our R&D work includes early-stage plasma-derives development programs, as well as post marketing clinical studies for Cytogam, our FDA-approved anti-CMV IgG. In 2025 the Company launched a research program, directed at advancing CMV disease management through novel strategies, and investigating potential new applications of Cytogam.